Bionpharma is dedicated to serving diverse needs. We specialize in researching, developing, and manufacturing generic drugs and over-the-counter products. Discover more about our …

Bionpharma operates as a pharmaceutical company specializing in the development of generic pharmaceutical products. We manufacture, market, and distribute over 50 drugs in the US and …

2007年10月24日 · Bionpharma Inc. manufactures, markets and/or distributes more than 47 drugs in the U.S.

2017年12月8日 · BION-1301 is a first-in-class humanized antibody targeting APRIL (TNFSF13). We demonstrated that BION-1301 inhibits proliferation and survival of tumor cells and …

Background: BION-1301 (BION) is first in class humanized monoclonal antibody directed against a proliferation-inducing ligand (APRIL) for treatment of relapsed/refractory (R/R) multiple …

Launched in 2014, BionPharma was founded by a team of executives and professionals with years of cumulative experience in the generics industry. Bionpharma’s goals are to develop …

2016年12月2日 · In vivo, BION-1301 was shown to suppress human APRIL induced T cell-independent B cell responses to NP-Ficoll. Biophysical and functional experiments indicated …

2022年11月16日 · BION-1301是结合并阻断增殖诱导配体（APRIL）的新型人源化单克隆抗体（mAb），具备潜在IgA肾病疾病修饰机制 （disease-modifying MOA）。 APRIL结合于B细 …

This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune …

BION-1301 EXPERIMENTAL 600mg subcutaneous administration every 2 weeks for 104 weeks DRUG BION-1301